| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Mixed Poisson Regression Model for Analysis of Patent Data |
0 |
0 |
0 |
290 |
2 |
2 |
4 |
1,742 |
| Are All Patent Examiners Equal? The Impact of Examiner Characteristics |
0 |
0 |
0 |
366 |
1 |
3 |
6 |
2,009 |
| Balancing Incentives: The Tension Between Basic and Applied Research |
0 |
0 |
1 |
419 |
0 |
0 |
4 |
1,886 |
| Characteristics of Demand for Pharmaceutical Products: an Examination of four Cephalosporins |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
2,373 |
| Deals Not Done: Sources of Failure in the Market for Ideas |
0 |
0 |
0 |
31 |
1 |
2 |
3 |
100 |
| Do Patents Matter?: Empirical Evidence after GATT |
0 |
0 |
0 |
297 |
0 |
0 |
0 |
819 |
| Entry and Patenting in the Software Industry |
0 |
0 |
1 |
191 |
1 |
1 |
8 |
644 |
| Faster, Smaller, Cheaper: An Hedonic Price Analysis of PDAs |
0 |
0 |
0 |
101 |
0 |
0 |
1 |
401 |
| Generics and New Goods in Pharmaceutical Price Indexes |
0 |
0 |
0 |
266 |
0 |
2 |
3 |
1,211 |
| Gone But Not Forgotten: Labor Flows, Knowledge Spillovers, and Enduring Social Capital |
0 |
0 |
0 |
269 |
0 |
4 |
7 |
842 |
| Hedonic Analysis of Arthritis Drugs |
0 |
0 |
0 |
163 |
0 |
1 |
3 |
1,017 |
| Industry Effects and Appropriability Measures in the Stock Markets Valuation of R&D and Patents |
0 |
0 |
3 |
390 |
0 |
0 |
5 |
1,167 |
| Is Distance from Innovation a Barrier to the Adoption of Artificial Intelligence? |
0 |
0 |
18 |
23 |
0 |
2 |
29 |
45 |
| Is Distance from Innovation a Barrier to the Adoption of Artificial Intelligence? |
0 |
0 |
18 |
19 |
2 |
4 |
22 |
27 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
0 |
0 |
0 |
157 |
0 |
0 |
3 |
1,636 |
| Is distance from innovation a barrier to the adoption of artificial intelligence |
0 |
1 |
12 |
21 |
1 |
6 |
25 |
37 |
| Is distance from innovation a barrier to the adoption of artificial intelligence |
1 |
1 |
19 |
19 |
1 |
2 |
33 |
33 |
| Market Conditions and Retirement of Physical Capital: Evidence fron Oil Tankers |
0 |
0 |
0 |
44 |
3 |
3 |
3 |
476 |
| Measuring competence?: exploring firm effects in pharmaceutical research |
0 |
0 |
0 |
510 |
0 |
0 |
6 |
1,343 |
| Not Invented Here? Innovation in Company Towns |
0 |
0 |
0 |
83 |
1 |
2 |
3 |
334 |
| Patent Thickets, Licensing and Innovative Performance |
0 |
0 |
1 |
130 |
1 |
3 |
6 |
416 |
| Patent thickets, licensing and innovative performance |
0 |
0 |
0 |
58 |
2 |
2 |
2 |
154 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
0 |
30 |
0 |
1 |
4 |
101 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
0 |
74 |
0 |
0 |
2 |
161 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
0 |
52 |
0 |
1 |
1 |
117 |
| Patents and the Survival of Internet-related IPOs |
0 |
0 |
0 |
84 |
4 |
4 |
4 |
297 |
| Patents and the global diffusion of new drugs |
0 |
0 |
1 |
20 |
1 |
3 |
4 |
91 |
| Patents and the global diffusion of new drugs |
0 |
0 |
0 |
54 |
0 |
0 |
0 |
86 |
| Patents, Thickets, and the Financing of Early-Stage Firms: Evidence from the Software Industry |
0 |
0 |
2 |
104 |
1 |
3 |
6 |
352 |
| Price Indexes for Clinical Trial Research: A Feasibility Study |
0 |
0 |
3 |
32 |
0 |
4 |
14 |
119 |
| Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research |
0 |
0 |
1 |
125 |
2 |
2 |
7 |
369 |
| Public-Private Interaction and the Productivity of Pharmaceutical Research |
0 |
0 |
1 |
189 |
0 |
2 |
6 |
766 |
| Racing or spilling?: the determinants of research productivity in ethical drug discovery |
0 |
0 |
0 |
53 |
1 |
1 |
2 |
189 |
| Racing to invest?: the dynamics of competition in ethical drug discovery |
0 |
0 |
1 |
297 |
1 |
1 |
4 |
602 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in Drug Discovery |
0 |
0 |
0 |
1 |
1 |
2 |
5 |
499 |
| Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry |
0 |
0 |
2 |
362 |
0 |
0 |
10 |
1,084 |
| Scale, scope and spillovers: the determinants of research productivity in ethical drug discovery |
0 |
0 |
0 |
145 |
1 |
2 |
5 |
331 |
| The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research |
0 |
0 |
2 |
310 |
1 |
6 |
23 |
1,975 |
| The Impact of Artificial Intelligence on Innovation |
2 |
5 |
31 |
418 |
22 |
60 |
209 |
3,404 |
| The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales Following Loss of Exclusivity |
0 |
0 |
0 |
56 |
1 |
2 |
6 |
105 |
| University Research, Industrial R&D, and the Anchor Tenant Hypothesis |
0 |
0 |
1 |
229 |
0 |
2 |
7 |
950 |
| Why are Some Regions More Innovative than Others? The Role of Firm Size Diversity |
0 |
0 |
1 |
101 |
1 |
2 |
6 |
289 |
| Why are some regions more innovative than others? The role of firm size diversity |
0 |
0 |
0 |
87 |
0 |
1 |
1 |
90 |
| Total Working Papers |
3 |
7 |
119 |
6,670 |
53 |
138 |
506 |
30,689 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery |
2 |
3 |
10 |
29 |
3 |
7 |
42 |
101 |
| Access to intellectual property for innovation: Evidence on problems and coping strategies from German firms |
0 |
0 |
1 |
24 |
2 |
2 |
7 |
127 |
| Analysis of Patent Data--A Mixed-Poisson-Regression-Model Approach |
0 |
0 |
0 |
0 |
2 |
3 |
4 |
936 |
| Canada’s Patent Productivity Paradox: Recent Trends and Implications for Future Productivity Growth |
4 |
5 |
11 |
16 |
5 |
7 |
56 |
79 |
| Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins |
0 |
0 |
1 |
411 |
2 |
2 |
10 |
1,172 |
| Deals not done: Sources of failure in the market for ideas |
0 |
0 |
2 |
9 |
1 |
1 |
6 |
81 |
| Diffusion of New Drugs in the Post-TRIPS Era |
0 |
0 |
1 |
54 |
0 |
0 |
2 |
170 |
| Entry and Patenting in the Software Industry |
0 |
0 |
0 |
44 |
4 |
4 |
11 |
254 |
| Faster, smaller, cheaper: an hedonic price analysis of PDAs |
0 |
0 |
0 |
41 |
2 |
3 |
4 |
261 |
| Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy |
0 |
1 |
1 |
27 |
1 |
3 |
6 |
106 |
| Generics and New Goods in Pharmaceutical Price Indexes |
0 |
0 |
1 |
234 |
1 |
2 |
7 |
932 |
| Generics and New Goods in Pharmaceutical Price Indexes: Reply |
0 |
0 |
0 |
35 |
0 |
0 |
1 |
171 |
| Industry Effects and Appropriability Measures in the Stock Market's Valuation of R&D and Patents |
1 |
1 |
5 |
365 |
2 |
2 |
22 |
1,253 |
| Information Technology and Intangible Output: The Impact of IT Investment on Innovation Productivity |
1 |
1 |
7 |
46 |
1 |
4 |
19 |
153 |
| Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs |
0 |
0 |
0 |
29 |
2 |
2 |
4 |
392 |
| Measuring Competence? Exploring Firm Effects in Pharmaceutical Research |
1 |
1 |
2 |
19 |
2 |
6 |
24 |
137 |
| New Pills for Poor People? Empirical Evidence after GATT |
0 |
0 |
2 |
239 |
0 |
1 |
5 |
523 |
| Not Invented Here? Innovation in company towns |
0 |
0 |
0 |
51 |
0 |
0 |
7 |
367 |
| Opportunity costs and entrepreneurial activity |
1 |
1 |
1 |
159 |
2 |
3 |
6 |
476 |
| Patent thickets, licensing and innovative performance |
0 |
0 |
0 |
44 |
0 |
1 |
7 |
164 |
| Patents and the Global Diffusion of New Drugs |
0 |
0 |
1 |
78 |
5 |
7 |
17 |
399 |
| Patents and the survival of Internet-related IPOs |
0 |
0 |
2 |
98 |
1 |
4 |
11 |
411 |
| Patents, Thickets and the Financing of Early‐Stage Firms: Evidence from the Software Industry |
0 |
0 |
4 |
80 |
3 |
5 |
16 |
356 |
| Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs |
0 |
0 |
1 |
5 |
3 |
4 |
13 |
43 |
| Pharmaceutical Innovations and Market Dynamics: Tracking Effects on Price Indexes for Antidepressant Drugs |
0 |
0 |
0 |
0 |
2 |
3 |
6 |
23 |
| Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research |
0 |
0 |
0 |
15 |
1 |
2 |
7 |
103 |
| Racing To Invest? The Dynamics of Competition in Ethical Drug Discovery |
0 |
0 |
1 |
12 |
1 |
1 |
10 |
646 |
| Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research |
0 |
2 |
3 |
262 |
0 |
3 |
12 |
650 |
| Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery |
1 |
2 |
6 |
634 |
3 |
5 |
26 |
1,960 |
| The Economics of Reproducibility in Preclinical Research |
0 |
0 |
1 |
10 |
4 |
6 |
13 |
63 |
| The Global Location of Biopharmaceutical Knowledge Activity: New Findings, New Questions |
0 |
0 |
0 |
6 |
1 |
1 |
3 |
52 |
| The Impact of Incremental Innovation in Biopharmaceuticals |
0 |
0 |
1 |
18 |
0 |
1 |
5 |
69 |
| The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems |
0 |
0 |
8 |
217 |
5 |
8 |
26 |
705 |
| Untangling the origins of competitive advantage |
0 |
1 |
3 |
9 |
2 |
4 |
6 |
37 |
| Why are some regions more innovative than others? The role of small firms in the presence of large labs |
1 |
1 |
1 |
81 |
3 |
5 |
15 |
334 |
| Total Journal Articles |
12 |
19 |
77 |
3,401 |
66 |
112 |
436 |
13,706 |
LogEc is hosted by the
Örebro University School of Business.